Innocan Pharma
Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

SYNOPSYS WKN: 883703 ISIN: US8716071076 Kürzel: SNPS Forum: Aktien Thema: Hauptdiskussion

500,38 EUR
+0,13 %+0,65
4. May, 12:59:13 Uhr, Lang & Schwarz
Kommentare 123
Barren_Wuffett
Barren_Wuffett, 24.05.2021 11:35 Uhr
0
ARK ist mittlerweile komplett aus Synopsys raus. Finde ich gut, so ist weniger Volatilität und mehr Langfristigkeit gegeben
Brokerjays
Brokerjays, 21.05.2021 19:09 Uhr
0
Tip top... überlege nochmal nachzulegen. Nvidia kündigt gerade einen Aktiensplit an, das treibt i.d.R. auch
Chefkoch82
Chefkoch82, 19.05.2021 23:06 Uhr
0
Guidance auch angehoben 😊
Brokerjays
Brokerjays, 19.05.2021 22:43 Uhr
0
Die liefert und liefert. Beim jetzigem Kurs könnte man gut Aufstocken
Chefkoch82
Chefkoch82, 19.05.2021 22:15 Uhr
2
Synopsys (NASDAQ:SNPS): FQ2 Non-GAAP EPS of $1.70 beats by $0.17; GAAP EPS of $1.24 beats by $0.22. Revenue of $1.02B ( 18.4% Y/Y) beats by $31.33M. Adjusted segment operating margin of 31% vs. 25.7% a year ago. Shares 2.4%.
Rarosch
Rarosch, 19.04.2021 11:42 Uhr
0
📍
Chefkoch82
Chefkoch82, 15.04.2021 21:16 Uhr
1
Renesas selects Synopsys' AI design system for advanced auto chip production
Chefkoch82
Chefkoch82, 13.04.2021 6:47 Uhr
0
Synopsys acquires MorethanIP to expand Ethernet IP portfolio
Chefkoch82
Chefkoch82, 07.04.2021 7:16 Uhr
1
Synopsys is one of the world’s largest software companies and specializes in Electronic design automation (EDA), also known as electronic computer-aided design (ECAD). While the company operates in close proximity to the semiconductor sector, it is not impacted by the cyclical nature of the chip industry. Synopsys isn’t a semiconductor manufacturer per se but provides the tools for engineers to test and design cutting-edge semiconductors. The company delivered a strong display in its latest quarterly financial report. Revenue hit $970.32 million, increasing by 16.3% year-over-year, and beating the consensus estimates by $15.95 million. There was a beat on the bottom-line, too, as Non-GAAP EPS of $1.52 came ahead of Wall Street’s forecast by $0.06 That said, after shares appreciated by 83% throughout 2020, the stock has found 2021 tough going, and sits slightly in the red. RBC’s Mitch Steves, however, expects that to change over the next 12 months. The 5-star analyst, rated #15 overall on TipRanks, noted, “Synopsys has a record of stable operations, a well-managed order pipeline, and predictable earnings. We expect it to benefit from an improving pricing environment in the sector and strong growth in IP offerings. We expect earnings growth above normalized EPS growth for semiconductor companies, with almost no volatility.” Steves added, “We see no change to the fundamental thesis and continue to believe that EDA is one of the best (if not the best) ways to invest in semiconductor growth long-term without material business volatility. Net Net: we remain positive on shares of SNPS.” In line with his optimistic approach, Steves rates SNPS an Outperform (i.e. Buy) along with a $330 price target. The implication for investors? Upside of 28% from current levels. (To watch Steves’ track record, click here) Steves’ positive outlook resonates with almost all his colleagues. Barring 1 Hold, all 9 other reviews say Buy, culminating in a Strong Buy consensus rating. The average price target currently stands at $318.89, suggesting gains of ~24% in the year ahead.
Chefkoch82
Chefkoch82, 06.04.2021 10:27 Uhr
0
https://www.tipranks.com/news/synopsys-to-repurchase-100m-in-stock-street-remains-bullish/
Chefkoch82
Chefkoch82, 24.03.2021 21:33 Uhr
0
https://seekingalpha.com/news/3675827-synopsys-and-keysight-collab-on-integrated-custom-design-flow-for-5g-systems
Investo
Investo, 27.02.2021 13:42 Uhr
0
Den Rücksetzer könnte man ausnutzen zum Nachkaufen:)
Hope!!
Hope!!, 23.02.2021 15:03 Uhr
0
.
Chefkoch82
Chefkoch82, 17.02.2021 22:13 Uhr
1
Synopsys (NASDAQ:SNPS): Q1 Non-GAAP EPS of $1.52 beats by $0.06; GAAP EPS of $1.03 misses by $0.04. Revenue of $970.32M ( 16.3% Y/Y) beats by $15.95M.
Investo
Investo, 11.02.2021 18:55 Uhr
0
Top Aktie
Meistdiskutiert
Thema
1 NEL ASA Hauptdiskussion +0,07 %
2 BTC/USD Hauptdiskussion +1,45 %
3 Bionano - Gang- Clubhouse ±0,00 %
4 Myriad International Holdings Hauptdiskussion +0,05 %
5 Palantir ±0,00 %
6 Rivian ±0,00 %
7 Nantkwest / Immunitybio -> IBRX -1,75 %
8 Lucid Group -1,55 %
9 CompuGroup +0,07 %
10 RWE Hauptdiskussion +0,06 %
Alle Diskussionen
Anzeige Weltweit handeln ab 0 Euro - Zum Depot
Aktien
Thema
1 NEL ASA Hauptdiskussion +0,07 %
2 Bionano - Gang- Clubhouse ±0,00 %
3 Myriad International Holdings Hauptdiskussion +0,05 %
4 Palantir ±0,00 %
5 Rivian ±0,00 %
6 Nantkwest / Immunitybio -> IBRX -1,75 %
7 Lucid Group -1,55 %
8 CompuGroup +0,07 %
9 RWE Hauptdiskussion +0,06 %
10 Gamestop💎🙌 +0,95 %
Alle Diskussionen